The increased level of COX-dependent arachidonic acid metabolism in blood platelets from secondary progressive multiple sclerosis patients

Molecular and Cellular Biochemistry

Volumn 420, Issue 1-2, 2016, Pages 85-94

  Morel, Agnieszka ^a   Miller, Elzbieta ^b,c   Bijak, Michal ^a   Saluk, Joanna ^a  

^a UNIVERSITY OF LODZ   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c Rehabilitation Ward   (Poland)

Author keywords

Arachidonic acid; Blood platelets; Cyclooxygenase; Multiple sclerosis

Indexed keywords

ARACHIDONIC ACID; MALONALDEHYDE; PROSTAGLANDIN SYNTHASE; THROMBOXANE B2;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIPID PEROXIDATION; MALE; METABOLISM; MULTIPLE SCLEROSIS; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA; ADULT; BLOOD; MIDDLE AGED;

ADULT; BLOOD PLATELETS; FEMALE; HUMANS; LIPID PEROXIDATION; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PLATELET AGGREGATION; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; THROMBOXANE B2;

EID: 84981210892     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-016-2770-6     Document Type: Article

References (58)

1. Popescu BF, Pirko I, Lucchinetti CF (2013) Pathology of multiple sclerosis: where do we stand? Continuum (Minneap Minn) 4:901–921
2. Cramer SP, Simonsen H, Frederiksen JL, Rostrup E, Larsson HB (2013) Abnormal blood–brain barrier permeability in normal appearing white matter in multiple sclerosis investigated by MRI. Neuroimage Clin 4:182–189
3. Fitzner D, Simons M (2010) Chronic progressive multiple sclerosis: pathogenesis of neurodegeneration and therapeutic strategies. Curr Neuropharmacol 3:305–315
4. Miller E (2012) Multiple sclerosis. Adv Exp Med Biol 724:222–238
5. Christiansen CF, Christensen S, Farkas DK, Miret M, Sørensen HT, Pedersen L (2010) Risk of arterial cardiovascular diseases in patients with multiple sclerosis: a population-based cohort study. Neuroepidemiology 35:267–274
6. Jadidi E, Mohammadi M, Moradi T (2013) High risk of cardiovascular diseases after diagnosis of multiple sclerosis. Mult Scler 19:1336–1340
7. Behari M, Shrivastava M (2013) Role of platelets in neurodegenerative diseases: a universal pathophysiology. Int J Neurosci 5:287–299
8. Engelhardt B, Ransohoff RM (2005) The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol 26:485–495
9. Morel A, Bijak M, Miller E, Miller S, Saluk J. Oxidative damage of blood platelets correlates with the degree of psycho-physical disability in secondary progressive MS (under review)
10. Palumbo S, Toscano CD, Parente L, Weigert R, Bosetti F (2011) Time-dependent changes in the brain arachidonic acid cascade during cuprizone-induced demyelination and remyelination. Prostaglandins Leukot Essent Fatty Acids 1:29–35
11. Ting HJ, Khasawneh FT (2010) Platelet function and isoprostane biology. Should isoprostanes be the newest member of the orphan-ligand family? J Biomed Sci 1:24
12. Májek P, Reicheltová Z, Štikarová J, Suttnar J, Sobotková A, Dyr JE (2010) Proteome changes in platelets activated by arachidonic acid, collagen, and thrombin. Proteome Sci 8:56
13. Warner TD, Nylander S, Whatling C (2011) Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy. Br J Clin Pharmacol 4:619–633
14. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373:1849–1860
15. Yagami T, Koma H, Yamamoto Y (2015) Pathophysiological roles of cyclooxygenases and prostaglandins in the central nervous system. Mol Neurobiol 53:1–18
16. Sobolewski C, Cerella C, Dicato M, Ghibelli L, Diederich M (2010) The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies. Int J Cell Biol 2010:215158
17. Hsieh HL, Yang CM (2013) Role of redox signaling in neuroinflammation and neurodegenerative diseases. Biomed Res Int 2013:484613
18. Morris G, Berk M (2015) The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disorders. BMC Med 13:68
19. Fischer MT, Sharma R, Lim JL, Haider L, Frischer JM, Drexhage J, Mahad D, Bradl M, van Horssen J, Lassmann H (2012) NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. Brain 135:886–899
20. Campbell GR, Mahad DJ (2012) Clonal expansion of mitochondrial DNA deletions and the progression of multiple sclerosis. CNS Neurol Disord: Drug Targets 11:589–597
21. Witte ME, Nijland PG, Drexhage JA, Gerritsen W, Geerts D, van Het Hof B, Reijerkerk A, de Vries HE, van der Valk P, van Horssen J (2013) Reduced expression of PGC-1α partly underlies mitochondrial changes and correlates with neuronal loss in multiple sclerosis cortex. Acta Neuropathol 125:231–243
22. Mao P, Reddy PH (2010) Is multiple sclerosis a mitochondrial disease? Biochim Biophys Acta 1:66–79
23. Carvalho KS (2013) Mitochondrial dysfunction in demyelinating diseases. Semin Pediatr Neurol 3:194–201
24. Lubin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis results of an international survey. National Multiple Sclerosis Society USA Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46:907–911
25. Walkowiak B, Michalak E, Koziołkiewicz W, Cierniewski CS (1989) Rapid photometric method for estimation of platelet count in blood plasma or platelet suspension. Thromb Res 56:763–766
26. Olas B, Saluk-Juszczak J, Pawlaczyk I, Nowak P, Kolodziejczyk J, Gancarz R, Wachowicz B (2006) Antioxidant and antiaggregatory effects of an extract from Conyza canadensis on blood platelets in vitro. Platelets 17:354–360
27. Patrono C, García Rodríguez LA, Landolfi R, Baigent C (2005) Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353:2373–2383
28. Chen J, Zuo S, Wang J, Huang J, Zhang X, Liu Y, Zhang Y, Zhao J, Han J, Xiong L, Shi M, Liu Z (2014) Aspirin promotes oligodendrocyte precursor cell proliferation and differentiation after white matter lesion. Front Aging Neurosci 6:7
29. Modi KK, Sendtner M, Pahan K (2013) Up-regulation of ciliary neurotrophic factor in astrocytes by aspirin. Implications for remyelination in multiple sclerosis. J Biol Chem 25:18533–18545
30. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G (2004) Platelet-active drugs: the relationships among dose, effectiveness, and side effects. In: The 7th ACCP conference on antithrombotic and thrombolytic therapy, Chest vol 3, pp 234–264
31. Aïd S, Bosetti F (2011) Targeting cyclooxygenases-1 and -2 in neuroinflammation: therapeutic implications. Biochimie 1:46–51
32. Marnett LJ (2000) Cyclooxygenase mechanisms. Curr Opin Chem Biol 4:545–552
33. Huang JS, Ramamurthy SK, Lin X, Le Breton GC (2004) Cell signalling through thromboxane A2 receptors. Cell Signal 5:521–533
34. Rao GH, White JG (1985) Role of arachidonic acid metabolism in human platelet activation and irreversible aggregation. Am J Hematol 4:339–347
35. Marcos-Ramiro B, Oliva Nacarino P, Serrano-Pertierra E, Blanco-Gelaz MA, Weksler BB, Romero IA, Couraud PO, Tuñón A, López-Larrea C, Millán J, Cernuda-Morollón E (2014) Microparticles in multiple sclerosis and clinically isolated syndrome: effect on endothelial barrier function. BMC Neurosci 15:110
36. Morel A, Bijak M, Miller E, Rywaniak J, Miller S, Saluk J (2015) Relationship between the increased haemostatic properties of blood platelets and oxidative stress level in multiple sclerosis patients with the secondary progressive stage. Oxid Med Cell Longev 2015:240918
37. Kuenz B, Lutterotti A, Khalil M, Ehling R, Gneiss C, Deisenhammer F, Reindl M, Berger T (2005) Plasma levels of soluble adhsion molecules sPECAM- 1, sP-selectin and sE-selectin are associated with relapsing/remitting disease course in multiple sclerosis. J Neuroimmunol 167:143–149
38. Callea L, Arese M, Orlandini A, Bargnani S, Priori A, Bussolino F (1999) Platelet activating factor is elevated in cerebral spinal fluid and plasma of patients with relapsing-remitting multiple sclerosis. J Neuroimmunol 94:212–221
39. Sáenz-Cuesta M, Irizar H, Castillo-Triviño T, Muñoz-Culla M, Osorio-Querejeta I, Prada A, Sepúlveda L, López-Mato MP, López de Munain A, Comabella M, Villar LM, Olascoaga J, Otaegui D (2014) Circulating microparticles reflect treatment effects and clinical status in multiple sclerosis. Biomark Med 5:653–661
40. Olerup O, Hillert J, Fredrikson S, Olsson T, Kam-Hansen S, Möller E, Carlsson B, Wallin J (1989) Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct disease entities. Proc Natl Acad Sci USA 18:7113–7117
41. Chen S, Su Y, Wang J (2013) ROS-mediated platelet generation: a microenvironment-dependent manner for megakaryocyte proliferation, differentiation, and maturation. Cell Death Dis 7:e722
42. Zhenyu Li M, Delaney K, O’Brien KA, Xiaoping D (2010) Signaling during platelet adhesion and activation. Arterioscler Thromb Vasc Biol 12:2341–2349
43. Brash AR (2001) Arachidonic acid as a bioactive molecule. J Clin Invest 11:1339–1345
44. Habets KL, Huizinga TW, Toes RE (2012) Platelets and autoimmunity. Eur J Clin Invest 7:746–757
45. Langer HF, Choi EY, Zhou H, Schleicher R, Chung KJ, Tang Z, Göbel K, Bdeir K, Chatzigeorgiou A, Wong C, Bhatia S, Kruhlak MJ, Rose JW, Burns JB, Hill KE, Qu H, Zhang Y, Lehrmann E, Becker KG, Wang Y, Simon DI, Nieswandt B, Lambris JD, Li X, Meuth SG, Kubes P, Chavakis T (2012) Platelets contribute to the pathogenesis of experimental autoimmune encephalomyelitis. Circ Res 9:1202–1210
46. Gironi M, Borgiani B, Mariani E, Cursano C, Mendozzi L, Cavarretta R, Saresella M, Clerici M, Comi G, Rovaris M, Furlan R (2014) Oxidative stress is differentially present in multiple sclerosis courses, early evident, and unrelated to treatment. J Immunol Res 2014:961863
47. Ortiz GG, Pacheco-Moisés FP, Bitzer-Quintero OK, Ramírez-Anguiano AC, Flores-Alvarado LJ, Ramírez-Ramírez V, Macias-Islas MA, Torres-Sánchez ED (2013) Immunology and oxidative stress in multiple sclerosis: clinical and basic approach. Clin Dev Immunol 2013:708659
48. Haider L (2015) Inflammation, iron, energy failure, and oxidative stress in the pathogenesis of multiple sclerosis. Oxid Med Cell Longev 2015:725370
49. Wachowicz B (2015) Blood platelets as a peripheral cell in oxidative stress in psychiatric disorders. In: Dietrich-Muszalska A, Chauhan V, Grignon S (eds) Studies on psychiatric disorders. Springer, New York, pp 327–353
50. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J (2011) Epidemiology and etiology of Parkinson’s disease: a review of the evidence. Eur J Epidemiol 1:1–58
51. Miller E, Walczak A, Saluk J, Ponczek MB, Majsterek I (2012) Oxidative modification of patient’s plasma proteins and its role in pathogenesis of multiple sclerosis. Clin Biochem 1–2:26–30
52. Nurden AT (2011) Platelets, inflammation and tissue regeneration. Thromb Haemost 105:13–33
53. Gutowicz M (2011) The influence of reactive oxygen species on the central nervous system. Postep Hig Med Dos 6:104–113
54. Pacher P, Beckman JS, Liaudet L (2007) Nitric oxide and peroxynitrite in health and disease. Physiol Rev 1:315–424
55. Krotz F, Sohn HY, Pohl U (2004) Reactive oxygen species: players in the platelet game. Arterioscler Thromb Vasc Biol 24:1988–1996
56. − production rates differentially regulate oxidative, nitroxidative, and nitrosative stress in the microcirculation. Free Radic Biol Med 63:161–174
57. Khan N, Farooq AD, Sadek B (2015) Investigation of cyclooxygenase and signaling pathways involved in human platelet aggregation mediated by synergistic interaction of various agonists. Drug Des Dev Ther 9:3497–3506
58. Lei J, Zhou Y, Xie D, Zhang Y (2015) Mechanistic insights into a classic wonder drug–aspirin. Am Chem Soc 1:70–73